Bassaganya-Riera Josep's Form 4 filing
Landos Biopharma, Inc. (LABP) · filed Dec 8, 2021
- Accession no.
- 0001843575-21-000007
- Filed
- Dec 8, 2021
- Trade date
- Dec 6-8, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions. Open-market sales total $668.3K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bassaganya-Riera JosepCIK 0001843575 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 6, 2021 | common stock | SSaleDisposed | −36,000 | $6.17 | −$222,120 | 5,390,046 | Indirect | |
| Dec 7, 2021 | common stock | SSaleDisposed | −42,000 | $6.58 | −$276,360 | 5,348,046 | Indirect | |
| Dec 8, 2021 | common stock | SSaleDisposed | −25,530 | $6.65 | −$169,774.5 | 5,322,516 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.